A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Savolitinib (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 25 Jan 2019 Status changed from recruiting to suspended.
- 16 Nov 2018 Planned End Date changed from 31 Aug 2020 to 31 Dec 2020.
- 16 Nov 2018 Planned primary completion date changed from 31 Aug 2020 to 31 Dec 2020.